Advertisement
Product › Details
SAGAsign® technology
Next higher product group | digital PCR technology (dPCR) | |
Status | 2020-01-28 sales existent | |
Organisation | Saga Diagnostics AB | |
Saga Diagnostics AB. (1/28/20). "Press Release: Saga Diagnostics Extends Its Collaboration with Servier to Use Ultrasensitive SAGAsafe Technology in Cancer Clinical Trials". Lund.
SAGA Diagnostics AB, a cancer liquid biopsy and genomic testing company focused on precision oncology and non-invasive ultrasensitive monitoring of cancer patients, today announces it has entered service agreements with the international pharmaceutical company Servier, based in Paris, France.
“These deals exemplify the increased demand we are experiencing for our offerings of ultrasensitive cancer analysis services and analysis kits. We are excited to be working with Servier, who continues to choose us for important translational oncology projects.”
– Lao Saal, CEO of SAGA Diagnostics.
The collaboration will be covering a total of three preclinical/clinical studies and is scheduled to run for approximately two years. In the course of these projects, SAGA Diagnostics will be developing assays and performing liquid biopsy tests on patients from multiple Servier clinical studies using the SAGAsafe® technology (formerly known as IBSAFE®) to identify and quantify circulating tumor DNA (ctDNA).
SAGAsafe® technology is a patented improvement of digital PCR that enables approximately 100-fold increased sensitivity compared to competitor methods, and can be used to quantify mutations in tissue samples as well as liquid biopsies such as blood plasma with unprecedented performance to a limit of detection of ~0.001% mutant allele frequency. The analyses will be run in the SAGA Diagnostics central laboratory in Lund, Sweden.
“We have been impressed by the service and ultra-sensitivity performance of SAGAsafe’s analyses and are looking forward to continue working together. Involving the SAGAsafe technology in these studies means that Servier will now be able to monitor effects at an earlier stage ensuring that we do not miss out on any insights.”
– Brian Lockhart, Director of CentEx-Biotechnology, Servier.
SAGAsafe® is part of a portfolio of ultrasensitive technologies, which also includes SAGAsign® (formerly known as KROMA™) for monitoring chromosomal rearrangements, as well as novel technologies in development. SAGA offers both off-the-shelf analysis services and kits as well as custom-tailored solutions to fit customers’ needs. SAGA’s molecular tools are being used in clinical trials and hospitals for detecting actionable mutations, monitoring treatment response, measuring minimal residual disease, and identifying resistance mechanisms to help direct therapy.
Contact:
Åke Nilsson, BD Director
bd@sagadiagnostics.com
Phone: +46 (0)733 01 72 42
About SAGA Diagnostics AB
SAGA Diagnostics is a personalized cancer genomics and disease monitoring company that offers molecular genetic testing of tissue biopsies and non-invasive “liquid biopsies” such as blood samples. SAGA helps pharmaceutical companies, scientists, and healthcare providers to detect actionable mutations, stratify patient groups, and monitor treatment response more accurately and to an industry-leading lower limit of detection of 0.001%. Analysis of circulating tumor DNA using these proprietary technologies gives SAGA unique ultrasensitivity, and provides the basis for optimal decision-making.
Follow us on Twitter @SAGAdiagnostics and LinkedIn.
Record changed: 2020-02-09 |
Advertisement
More documents for digital PCR technology (dPCR)
- [1] Johnson, Madeleine [GenomeWeb]. (11/16/23). "News: Stilla Focuses on Ease of Use With New Seven-Channel Digital PCR System". New York, NY....
- [2] Qiagen N.V.. (7/26/23). "Press Release: Bio-Rad and Qiagen Announce Patent Settlement and Cross-licensing Agreement". Venlo....
- [3] CellCarta. (12/14/21). "Press Release: CellCarta Acquires Biogazelle to Strengthen Its Genomic Capabilities and Expand into Digital PCR (dPCR) Services". Montréal....
- [4] Stilla Technologies S.A.S.. (11/23/21). "Press Release: Stilla Technologies Secures Financing of more than €31 Million Adding Casdin Capital and the European Investment Bank to Existing Investors". Paris & Boston, MA....
- [5] Stilla Technologies S.A.S.. (6/30/21). "Press Release: Stilla Technologies Strengthens Executive Team with Appointment of Matthew Grow, PhD, to Vice President Global Marketing and Commercial Operations". Boston, MA & Paris....
- [6] Stilla Technologies S.A.S.. (2/2/21). "Press Release: Stilla Expands Leadership Team to Drive Next Phase of Global Commercial Growth; Appoints Philippe Mourere as President and CEO and Founder Rémi Dangla as CTO". Boston, MA & Paris....
- [7] Stilla Technologies S.A.S.. (12/10/19). "Press Release: Stilla Technologies Names Key Leadership Slate to Support Global Growth of its Next-Generation Digital PCR Solution". Paris....
- [8] Stilla Technologies S.A.S.. (10/10/19). "Press Release: Stilla Technologies Opens U.S. Subsidiary for Direct Commercial Operations Under the Leadership of Life Science Veteran". Beverly, MA....
- [9] Formulatrix, Inc.. (1/10/19). "Press Release: Formulatrix Digital PCR Technology to Be Acquired by Qiagen". Bedford, MA....
- [10] Qiagen N.V.. (1/7/19). "Press Release: Qiagen Unveils Plans for Next-generation Digital PCR Systems". Hilden & Germantown, MD....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top